Catalyst Health Economics Consultants

Schizophrenia

1. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia.

Authors: JF Guest, WM Hart, RF Cookson & E Lindstrom.
Source: British Journal of Medical Economics 1996; 10: 59-67.

View Abstract

2. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia.

Presented at the 1996 Winter Meeting Of The Royal College Of Psychiatrists, Stratford Upon Avon, January 1996.

3. Economic impact of using risperidone (Risperdal™) to treat chronic schizophrenia in Ireland.

Presented at 6th World Congress of Biological Psychiatry, Nice, June 1997.

4. Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland.

Authors: WM Hart, E Lindstrom & JF Guest.
Source: Irish Journal of Psychiatry 1997; 16(3): 12-16.

View Abstract

5. Cost of schizophrenia to UK society: An incidence-based cost of illness model for the first five years following diagnosis.

Authors: JF Guest & RF Cookson.
Source: PharmacoEconomics 1999; 15(6): 610.

View Abstract

6. The costs and consequences of switching patients from typical antipsychotics to quetiapine.

Presented at the 14th ECNP Congress, Istanbul, October 2001.

View pdf


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018